Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA pseudoephedrine proposal should be "revisited," Sen. Hatch tells DEA conference.

This article was originally published in The Tan Sheet

Executive Summary

DEA PSEUDOEPHEDRINE REG "REVISIT" SUGGESTED BY SEN. HATCH at a Feb. 13 conference on illicit methamphetamine manufacture and use. The meeting was sponsored by the Drug Enforcement Agency and held in Arlington, Va. "We must strike a balance that weighs the benefits to law enforcement against the cost to industry," Sen. Orrin Hatch (R-Utah) declared. "We must not allow our need to restrict pseudoephedrine diversion to prevent the legitimate consumer from getting access to cold and allergy remedies and other important products."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel